Advanced Functional Materials,
Год журнала:
2023,
Номер
33(49)
Опубликована: Сен. 3, 2023
Abstract
The
complex
physiological
environment
in
bone
tissue
poses
a
challenge
to
the
efficient
delivery
of
chemotherapeutic
agents
for
osteosarcoma
(OS)
treatment;
hence,
an
drug
system
designed
OS
is
highly
desired.
Herein,
alendronate
(Ale)‐based
cationic
platinum
prodrug
nanoparticles
(Ale
NP)
are
developed,
which
exhibit
cascade
responsiveness
tumor
microenvironment.
With
Ale
triggered
targeting
and
charge
reversal
effects,
NP
demonstrates
superior
capacity
achieving
deep
penetration
into
dense
tissues.
Furthermore,
can
induce
dendritic
cell
(DC)
maturation
via
activation
cyclic
GMP‐AMP
synthase‐stimulator
interferon
genes
(cGAS‐STING)
pathway
using
drugs.
potent
phenanthridine
(Pt(II))
be
released
presence
overexpressed
glutathione
(GSH)
cells,
thereby
dual‐targeted
drugs
OS.
Notably,
not
only
effectively
eliminates
internal
region
but
also
acts
as
STING
agonist
reverse
suppressive
microenvironment
Overall,
Ale‐triggered
dual‐cascade
significantly
improve
OS,
hence
paving
promising
avenue
clinical
treatment
Advanced Materials,
Год журнала:
2022,
Номер
35(8)
Опубликована: Дек. 9, 2022
Tumor
metastases
and
reoccurrences
are
considered
the
leading
cause
of
cancer-associated
deaths.
While
highly
efficient
treatments
for
eradication
primary
tumors
have
been
developed,
treatment
secondary
or
metastatic
remains
poorly
accessible.
Over
past
years,
compounds
that
intervene
through
cyclic
GMP-AMP
synthase-stimulator
interferon
genes
(cGAS-STING)
signaling
pathway
against
tumor
emerged
with
potential
clinical
development.
stimulatory
DNAs
demonstrated
activation
this
pathway,
these
associated
poor
bioavailability,
stability,
cancer
selectivity,
hindering
their
use
therapeutic
applications.
Herein,
encapsulation
a
potent
chemotherapeutic
platinum(II)
complex
incorporation
DNA
strands
cGAS-STING
into
multimodal
tetrahedral
nanostructures
(84bp-TDNISD/56MESS
)
combined
chemotherapy
immunotherapy
is
reported.
It
found
84bp-TDNISD/56MESS
can
work
as
not
only
drug
delivery
carrier
toxins,
but
also
an
immunostimulant
agent
activate
STING
antitumor
immune
responses.
In
mouse
breast
model,
nanostructure
to
nearly
fully
eradicate
well
secondary/metastatic
tumors,
hence
demonstrating
its
translational
value.
Pharmaceutics,
Год журнала:
2022,
Номер
14(10), С. 1990 - 1990
Опубликована: Сен. 21, 2022
Cancer
immunotherapy
has
shown
impressive
anti-tumor
activity
in
patients
with
advanced
and
early-stage
malignant
tumors,
thus
improving
long-term
survival.
However,
current
cancer
is
limited
by
barriers
such
as
low
tumor
specificity,
poor
response
rate,
systemic
toxicities,
which
result
the
development
of
primary,
adaptive,
or
acquired
resistance.
Immunotherapy
resistance
complex
mechanisms
that
depend
on
interaction
between
cells
microenvironment
(TME).
Therefore,
targeting
TME
recently
received
attention
a
feasibility
strategy
for
re-sensitizing
resistant
neoplastic
niches
to
existing
immunotherapy.
With
nanotechnology,
nanoplatforms
possess
outstanding
features,
including
high
loading
capacity,
tunable
porosity,
specific
desired
locus.
can
significantly
improve
effectiveness
while
reducing
its
toxic
side
effects
non-target
receive
intense
This
review
explores
reprogramming
resistance,
TAMs,
CAFs,
vasculature,
hypoxia.
We
also
examined
whether
application
nano-drugs
combined
regimens
clinical
outcomes
solid
tumors.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 6, 2023
The
treatment
of
cancer
was
revolutionized
within
the
last
two
decades
by
utilizing
mechanism
immune
system
against
malignant
tissue
in
so-called
immunotherapy.
Two
main
developments
boosted
immunotherapy:
1)
use
checkpoint
inhibitors,
which
are
characterized
a
relatively
high
response
rate
mainly
solid
tumors;
however,
at
cost
serious
side
effects,
and
2)
chimeric
antigen
receptor
(CAR)-T
cells,
were
shown
to
be
very
efficient
hematologic
malignancies,
but
failed
show
clinical
effectiveness
tumors
until
now.
In
addition,
active
immunization
individual
is
emerging,
first
products
have
reached
approval.
These
new
options
cost-intensive
not
financially
compensated
health
insurance
many
countries.
Hence,
strategies
must
developed
make
immunotherapy
affordable
improve
cost-benefit
ratio.
this
review,
we
discuss
following
strategies:
leverage
antigenicity
“cold
tumors”
with
reagents,
microbiome-based
as
markers
or
therapeutics,
3)
apply
measures
that
adoptive
cell
therapy
(ACT)
cheaper,
e.g.,
off-the-shelf
products,
4)
immunotherapies
offer
cheaper
platforms,
such
RNA-
peptide-based
vaccines
shared
common
antigens
instead
highly
personal
antigens,
5)
small
set
predictive
biomarkers
“sequence
everything”
approach,
6)
explore
immunohistochemistry
may
direct
therapies.
Advanced Functional Materials,
Год журнала:
2023,
Номер
33(49)
Опубликована: Сен. 3, 2023
Abstract
The
complex
physiological
environment
in
bone
tissue
poses
a
challenge
to
the
efficient
delivery
of
chemotherapeutic
agents
for
osteosarcoma
(OS)
treatment;
hence,
an
drug
system
designed
OS
is
highly
desired.
Herein,
alendronate
(Ale)‐based
cationic
platinum
prodrug
nanoparticles
(Ale
NP)
are
developed,
which
exhibit
cascade
responsiveness
tumor
microenvironment.
With
Ale
triggered
targeting
and
charge
reversal
effects,
NP
demonstrates
superior
capacity
achieving
deep
penetration
into
dense
tissues.
Furthermore,
can
induce
dendritic
cell
(DC)
maturation
via
activation
cyclic
GMP‐AMP
synthase‐stimulator
interferon
genes
(cGAS‐STING)
pathway
using
drugs.
potent
phenanthridine
(Pt(II))
be
released
presence
overexpressed
glutathione
(GSH)
cells,
thereby
dual‐targeted
drugs
OS.
Notably,
not
only
effectively
eliminates
internal
region
but
also
acts
as
STING
agonist
reverse
suppressive
microenvironment
Overall,
Ale‐triggered
dual‐cascade
significantly
improve
OS,
hence
paving
promising
avenue
clinical
treatment
